Literature DB >> 6336942

The response to chemotherapy of a variety of human tumour xenografts.

G G Steel, V D Courtenay, M J Peckham.   

Abstract

The results of a series of projects on the cytotoxic drug response of human tumour xenografts are compared. All were performed in one laboratory, using conventional CBA mice that were usually immunosuppressed by thymectomy, cytosine arabinoside treatment, and whole-body irradiation. Results on human tumours arising in 9 anatomical sites are included, with the main emphasis on colo-rectal, pancreas, breast, lung and testis carcinomas, also melanomas. Growth acceleration during successive passage of most of these tumour types was observed. When therapeutic response was measured by a growth-delay method there were wide differences in response to chemotherapy. Testicular teratomas and small-cell lung tumours responded well; breast tumours showed modest response; melanomas, colo-rectal tumours and non-small-cell lung tumours responded poorly. Studies of clonogenic cell survival were made in 11 xenografted tumour lines. They confirmed the range of responsiveness and tendency towards individuality of the growth delay data. Cell survival in most cases was exponentially related to drug dose. This compilation of a large amount of experimental data supports the belief that human tumour xenografts broadly maintain the level of chemotherapeutic responsiveness of the source tumours in man.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6336942      PMCID: PMC2011242          DOI: 10.1038/bjc.1983.1

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  33 in total

1.  Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.

Authors:  E J Freireich; E A Gehan; D P Rall; L H Schmidt; H E Skipper
Journal:  Cancer Chemother Rep       Date:  1966-05

2.  The therapeutic response of three human tumor lines maintained in immune-suppressed mice.

Authors:  L Kopper; G G Steel
Journal:  Cancer Res       Date:  1975-10       Impact factor: 12.701

3.  Chemotherapy of a human malignant melanoma transplanted in the nude mouse.

Authors:  C O Povlsen; G K Jacobsen
Journal:  Cancer Res       Date:  1975-10       Impact factor: 12.701

4.  Tumour volume response, initial cell kill and cellular repopulation in B16 melanoma treated with cyclophosphamide and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.

Authors:  T C Stephens; J H Peacock
Journal:  Br J Cancer       Date:  1977-09       Impact factor: 7.640

5.  The growth kinetics of xenografts of human colorectal tumours in immune deprived mice.

Authors:  R G Pickard; L M Cobb; G G Steel
Journal:  Br J Cancer       Date:  1975-01       Impact factor: 7.640

6.  An in vitro colony assay for human tumours grown in immune-suppressed mice and treated in vivo with cytotoxic agents.

Authors:  V D Courtenay; J Mills
Journal:  Br J Cancer       Date:  1978-02       Impact factor: 7.640

7.  Improved immune-suppression techniques for the exongrafting of human tumours.

Authors:  G G Steel; V D Courtenay; A Y Rostom
Journal:  Br J Cancer       Date:  1978-02       Impact factor: 7.640

8.  Maintenance of biological and biochemical characteristics of human colorectal tumours during serial passage in immune-deprived mice.

Authors:  J A Houghton; D M Taylor
Journal:  Br J Cancer       Date:  1978-02       Impact factor: 7.640

9.  A colony-forming assay for human tumour xenografts using agar in diffusion chambers.

Authors:  I E Smith; V D Courtenay; M Y Gordon
Journal:  Br J Cancer       Date:  1976-11       Impact factor: 7.640

10.  Growth characteristics of human colorectal tumours during serial passage in immune-deprived mice.

Authors:  J A Houghton; D M Taylor
Journal:  Br J Cancer       Date:  1978-02       Impact factor: 7.640

View more
  48 in total

1.  Cell proliferation in human tumours growing in nude mice: renal cell carcinomas, larynx and hypopharynx carcinomas.

Authors:  B Maurer-Schultze; I D Bassukas; M Böswald; M Harasim
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

Review 2.  Antibody Drug Conjugates: Preclinical Considerations.

Authors:  Gadi G Bornstein
Journal:  AAPS J       Date:  2015-02-28       Impact factor: 4.009

3.  Evaluation of a conjugate of purified antibodies against human AFP-dextran-daunorubicin to human AFP-producing yolk sac tumor cell lines.

Authors:  K Ohkawa; N Hibi; Y Tsukada
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

Review 4.  Predictive testing in cancer chemotherapy. I. In vivo.

Authors:  P H Slee; A T Van Oosterom; E A De Bruijn
Journal:  Pharm Weekbl Sci       Date:  1985-06-21

Review 5.  Predictive tests in cancer chemotherapy. A reappraisal.

Authors:  R Osieka; S Seeber; C G Schmidt
Journal:  Klin Wochenschr       Date:  1984-03-01

6.  Oncolytic vaccinia virus therapy of salivary gland carcinoma.

Authors:  Natalya Chernichenko; Gary Linkov; Pingdong Li; Richard L Bakst; Chun-Hao Chen; Shuangba He; Yong A Yu; Nanhai G Chen; Aladar A Szalay; Yuman Fong; Richard J Wong
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2013-02       Impact factor: 6.223

7.  Clinical pharmacokinetics of oral CCNU (lomustine).

Authors:  F Y Lee; P Workman; J T Roberts; N M Bleehen
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

8.  Development of new anti-cancer drugs.

Authors:  H M Pinedo
Journal:  Med Oncol Tumor Pharmacother       Date:  1986

Review 9.  New cisplatin analogues in development. A review.

Authors:  Raymond B Weiss; Michaele C Christian
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

10.  Cytostatic drug testing in human leukemias by means of multiparametric flow cytometry.

Authors:  A Neubauer; H Sauer; G Valet
Journal:  Blut       Date:  1987-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.